- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03829787
Attentional Biases, Reward Sensitivity, and Cognitive Control in Adults With Bipolar Disorder
Attentional Biases, Reward Sensitivity, and Cognitive Control in Adults With Bipolar Disorder and Different Psychiatric Comorbidities: An Eye-Tracking Study
Study Overview
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Nicole Jones
- Phone Number: 216/844-2862
- Email: mdp@uhhospitals.org
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Recruiting
- University Hospitals Cleveland Medical Center - Mood Disorders Program
-
Contact:
- Nicole Jones, MA
- Phone Number: 216-844-2862
- Email: mdp@UHhospitals.org
-
Principal Investigator:
- Keming Gao, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion and Exclusion Criteria for Group 1: bipolar disorder without current anxiety or substance use disorder
- Inclusion Criteria for Group 1:
i. Male or female, age 18 or older
ii. Meets diagnostic criteria for lifetime bipolar I or II disorder according to Diagnostic and Statistical Manual-5 (DSM-5) criteria, as confirmed by the Mini International Neuropsychiatric Interview (MINI)
iii. Currently in a depressive episode or currently in remission from a mood episode
iv. Young Mania Rating Scale total score ≤ 8
v. In the opinion of the investigator, capable of understanding and complying with protocol requirements
vi. In the opinion of the investigator, has the competency to understand and sign the informed consent
vii. Subject is compliant with taking psychiatric medication(s) per the investigator's discretion
b. Exclusion Criteria for Group 1:
i. Significant structural brain lesion (e.g. infarct, hemorrhage, tumor, multiple sclerosis)
ii. Progressive neurological disease such as neurodegenerative disease
iii. Any current psychiatric disorder (other than a current depressive episode) including anxiety disorders, substance use disorders, antisocial personality disorder and borderline personality disorder as assessed by the MINI and clinician assessment.
iv. Currently pregnant or planning to become pregnant
v. Tests positive for illegal substances or prescription medications for which they do not have a valid prescription
vi. Currently taking any steroids, stimulants, or opioid pain killers.
vii. Meets DSM-5 criteria for any alcohol and/or drug use disorder within the last 6 months, excluding the use of caffeine.Currently experiencing nicotine use disorder or any smoking of cigarettes or use of other nicotine containing products within a week before the eye tracking visit.
viii. Has had electroconvulsive therapy (ECT) treatment within the last 6 months.
Inclusion and Exclusion Criteria for Group 2: Bipolar disorder with a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia)
a. Inclusion Criteria for Group 2:
i. Male or female, age 18 or older
ii. Meets diagnostic criteria for lifetime bipolar I or II disorder according to DSM-5 criteria, as confirmed by the Mini International Neuropsychiatric Interview (MINI)
iii. Currently in a depressive episode or currently in remission from a mood episode
iv. Meets diagnostic criteria for a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia) as confirmed by the Mini International Neuropsychiatric Interview (MINI)
v. Hamilton Anxiety Rating Scale total score ≥ 18
vi. Young Mania Rating Scale total score ≤ 8
vii. In the opinion of the investigator, capable of understanding and complying with protocol requirements
viii. In the opinion of the investigator, has the competency to understand and sign the informed consent
ix. Subject is compliant with taking psychiatric medication(s) per the investigator's discretion
b. Exclusion Criteria for Group 2:
i. Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis)
ii. Progressive neurological disease such as neurodegenerative disease
iii. Any co-occurring lifetime or current obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), or attention deficit hyperactivity disorder (ADHD)
iv. Meets criteria for antisocial personality disorder or borderline personality disorder as assessed by clinician assessment.
v. Currently pregnant or planning to become pregnant
vi. Tests positive for illegal substances or prescription medications for which they do not have a valid prescription
vii. Currently taking any steroids, stimulants, or opioid pain killers.
viii. Meets DSM-5 criteria for any alcohol and/or drug use disorder within the last 6 months, excluding the use of caffeine
ix. Currently experiencing nicotine use disorder or any smoking of cigarettes or use of other nicotine containing products within a week before the eye tracking visit.
x. Has had ECT treatment within the last 6 months.
Inclusion and Exclusion Criteria for Group 3: Bipolar disorder with a current anxiety disorder and a current substance use disorder
a. Inclusion Criteria for Group 3:
i. Male or female, age 18 or older
ii. Meets diagnostic criteria for lifetime bipolar I or II disorder according to the DSM-5 criteria, as confirmed by the Mini International Neuropsychiatric Interview (MINI)
iii. Meets diagnostic criteria for a substance use disorder within the last 3 months
iv. Meets diagnostic criteria for a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia) as confirmed by the Mini International Neuropsychiatric Interview (MINI)
v. Currently in a depressive episode or currently in remission from a mood episode
vi. Hamilton Anxiety Rating Scale total score ≥ 18
vii. Young Mania Rating Scale total score ≤ 8
viii. In the opinion of the investigator, capable of understanding and complying with protocol requirements
ix. In the opinion of the investigator, has the competency to understand and sign the informed consent
x. Subject is compliant with taking psychiatric medication(s) per the investigator's discretion
b. Exclusion Criteria for Group 3:
i. Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis)
ii. Progressive neurological disease such as neurodegenerative disease
iii. Any co-occurring lifetime or current obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), or attention deficit hyperactivity disorder (ADHD)
iv. Meets criteria for antisocial personality disorder or borderline personality disorder as assessed by clinician assessment.
v. Intoxicated or in acute withdrawal state.
vi. Currently pregnant or planning to become pregnant.
vii. Currently experiencing nicotine use disorder or any smoking of cigarettes or use of other nicotine containing products within a week before the eye tracking visit.
viii. Has had ECT treatment within the last 6 months.
Inclusion and Exclusion Criteria for Group 4: Bipolar disorder without an anxiety disorder but with a current substance use disorder
a. Inclusion Criteria for Group 4:
i. Male or female, age 18 or older
ii. Meets diagnostic criteria for lifetime bipolar I or II disorder according to the DSM-5 criteria, as confirmed by the Mini International Neuropsychiatric Interview (MINI)
iii. Meets diagnostic criteria for a substance use disorder within the last 3 months
iv. Currently in a depressive episode or currently in remission from a mood episode
v. Young Mania Rating Scale total score ≤ 8
vi. Hamilton Anxiety Rating Scale total score ≤ 12
vii. In the opinion of the investigator, capable of understanding and complying with protocol requirements
viii. In the opinion of the investigator, has the competency to understand and sign the informed consent
ix. Subject is compliant with taking psychiatric medication(s) per the investigator's discretion
b. Exclusion Criteria for Group 4:
i. Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis)
ii. Progressive neurological disease such as neurodegenerative disease
iii. Any co-occurring current anxiety disorder or attention deficit hyperactivity disorder (ADHD)
iv. Meets criteria for antisocial personality disorder or borderline personality disorder as assessed by clinician assessment.
v. Intoxicated or in an acute withdrawal state
vi. Currently pregnant or planning to become pregnant.
vii. Currently experiencing nicotine use disorder or any smoking of cigarettes or use of other nicotine containing products within a week before the eye tracking visit.
viii. Has had ECT treatment within the last 6 months.
Inclusion and exclusion criteria for Group 5: Healthy Volunteers
- Inclusion criteria for Group 5:
i. Male or female, age 18 or older
ii. In the opinion of the investigator, capable of understanding and complying with protocol requirements
iii. In the opinion of the investigator, has the competency to understand and sign the informed consent
iv. Physically healthy as determined by research psychiatrist
v. Without any current and/or lifetime psychiatric disorder as confirmed by the Mini International Neuropsychiatric Interview (MINI)
b. Exclusion Criteria for Group 5:
i. Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis)
ii. Progressive neurological disease such as neurodegenerative disease
iii. Any psychiatric disorder including any severe personality disorder
iv. Currently pregnant or planning to become pregnant
v. Tests positive for illegal substances or prescription medications for which they do not have a valid prescription
vi. Currently taking any steroids, stimulants, or opioid pain killers.
vii. Currently experiencing nicotine use disorder or any smoking of cigarettes or use of other nicotine containing products within a week before the eye tracking visit.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Healthy Volunteers
|
Subjects will be assessed for attentional biases, reward sensitivity, and cognitive control using eye tracking technology
|
Bipolar without Anxiety or Substance Use Disorder
Subjects who are diagnosed with bipolar disorder but do not have any current anxiety or substance use disorders
|
Subjects will be assessed for attentional biases, reward sensitivity, and cognitive control using eye tracking technology
|
Bipolar disorder with a current anxiety disorder only
Subjects who are diagnosed with bipolar disorder and a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia) but not a current substance use disorders
|
Subjects will be assessed for attentional biases, reward sensitivity, and cognitive control using eye tracking technology
|
Bipolar disorder with a current anxiety disorder and a current
Subjects who are diagnosed with bipolar disorder and a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia) AND a current substance use disorders
|
Subjects will be assessed for attentional biases, reward sensitivity, and cognitive control using eye tracking technology
|
Bipolar disorder with a current substance use disorder only
Subjects who are diagnosed with bipolar disorder & a substance use disorders but not a current anxiety disorder
|
Subjects will be assessed for attentional biases, reward sensitivity, and cognitive control using eye tracking technology
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measure the differences in attentional bias among the 5 groups by assessing how long it takes a subject to locate and fixate on each face on the screen
Time Frame: Baseline
|
This paradigm involves the simultaneous presentation of 2 facial images.
Two facial expressions (happy-neutral, sad-neutral, fearful-neutral, and neutral-neutral) from the same actor are presented simultaneously on each side of the screen.
For each participant, happy, sad, fearful, and neutral facial expressions are randomly assigned to each side with each emotion category presented on each side with equal frequency.
Each trial presents happy-neutral, sad-neutral, fearful-neutral and neutral-neutral facial expression in a new random order for each participant.
Each trial begins with a central cross, followed by presentation of facial stimuli for 250-500 ms.
Direction of gaze is measured with x and y coordinates.
The latency and velocity of eye movement will be measured.
Eye movements that are stable for more than 100 msec within 1˚of visual angle are classified as a fixation.
The time to locate the face and fixation time to each face will be compared.
|
Baseline
|
Measure the differences in reward sensitivity among the 5 groups by assessing the amplitude of the saccade to reward and non-reward stimuli
Time Frame: Baseline
|
The reward paradigm is to measure amplitude and velocity of saccades toward reward stimuli.
A saccade is a rapid eye movement made by the primate and human after they make their decision among several options.
The participant will be told that he/she will be rewarded for a making a correct saccade in response to congruent conditional stimulus and she/he will not be rewarded for making a correct saccade in response to an incongruent stimulus.
Each participant will have 5-10 trials to practice before the recording begins.
The velocity and amplitude of saccade to reward and non-reward stimuli will be recorded for each trials.
The mean velocity and amplitude to reward and non-reward stimuli among the different groups of patients will be compared.
|
Baseline
|
Measure the differences in reward sensitivity among the 5 groups by assessing the velocity of the saccade to reward and non-reward stimuli
Time Frame: Baseline
|
The reward paradigm is to measure amplitude and velocity of saccades toward reward stimuli.
A saccade is a rapid eye movement made by the primate and human after they make their decision among several options.
The participant will be told that he/she will be rewarded for a making a correct saccade in response to congruent conditional stimulus and she/he will not be rewarded for making a correct saccade in response to an incongruent stimulus.
Each participant will have 5-10 trials to practice before the recording begins.
The velocity and amplitude of saccade to reward and non-reward stimuli will be recorded for each trials.
The mean velocity and amplitude to reward and non-reward stimuli among the different groups of patients will be compared.
|
Baseline
|
Measure the differences in cognitive control among the 5 groups by assessing the amplitude of the antisaccade
Time Frame: Baseline
|
Antisaccade (AS) performance is a sensitive marker for cognitive control of behavior and executive functioning.
In contrast to saccade, antisaccade is an eye movement away from a target of reward or non-reward stimulus.
Commonly used antisaccade paradigm includes cue, preparation, and response execution.
In this protocol, the patients will learn to make an antisaccade to a reward or non-reward stimulus.
Patients will receive a reward for each correct antisaccade movement to reward stimuli.
The paradigm will include equal number of reward and non-reward trials.
Trials are pseudorandomized across runs.
For the reward condition, the value of any single correct response is intentionally ambiguous to prevent subjects from keeping a running total of earnings during the task.
|
Baseline
|
Measure the differences in cognitive control among the 5 groups by assessing the velocity of the antisaccade
Time Frame: Baseline
|
Antisaccade (AS) performance is a sensitive marker for cognitive control of behavior and executive functioning.
In contrast to saccade, antisaccade is an eye movement away from a target of reward or non-reward stimulus.
Commonly used antisaccade paradigm includes cue, preparation, and response execution.
In this protocol, the patients will learn to make an antisaccade to a reward or non-reward stimulus.
Patients will receive a reward for each correct antisaccade movement to reward stimuli.
The paradigm will include equal number of reward and non-reward trials.
Trials are pseudorandomized across runs.
For the reward condition, the value of any single correct response is intentionally ambiguous to prevent subjects from keeping a running total of earnings during the task.
|
Baseline
|
Collaborators and Investigators
Investigators
- Principal Investigator: Keming Gao, MD, PhD, University Hospitals Cleveland Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 09-17-03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bipolar Disorder
-
ProgenaBiomeRecruitingBipolar Disorder | Bipolar I Disorder | Bipolar II Disorder | Bipolar Type I Disorder | Bipolar Disorder Mild | Bipolar Disorder Moderate | Bipolar Disorder SevereUnited States
-
Rush University Medical CenterThe Ryan Licht Sang Bipolar FoundationCompletedBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar Disorder I | Bipolar Affective DisorderUnited States
-
University of PittsburghNational Alliance for Research on Schizophrenia and DepressionCompletedBipolar I Disorder | Bipolar II Disorder | Bipolar Disorder NOSUnited States
-
Region StockholmKarolinska InstitutetRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II Disorder | Bipolar Affective Disorder; Remission in | Bipolar Affective Disorder, Currently Depressed, ModerateSweden
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do Sul; Hospital Moinhos de VentoActive, not recruitingBipolar Disorder | Bipolar Depression | Major Depressive Disorder | Bipolar I Disorder | Affective Disorder | Bipolar II DisorderBrazil
-
Medical University of South CarolinaMilken InstituteCompletedBipolar Disorder | Bipolar I Disorder | Bipolar II DisorderUnited States
-
Mayo ClinicCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
-
Myriad Genetic Laboratories, Inc.University of MinnesotaCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
-
University Hospital, Strasbourg, FranceUnknownBipolar Disorder I | Bipolar Disorder II | Rapid Cycling Bipolar Disorder(DSM-IV-TR)France
-
Centre for Addiction and Mental HealthUniversity Health Network, TorontoNot yet recruitingBipolar Disorder | Bipolar Depression | Treatment- Resistant Bipolar Disorder | Type 2 Bipolar DisorderCanada
Clinical Trials on Eye tracking
-
Institut National de la Santé Et de la Recherche...CompletedHealthy | Parkinson Disease | DystoniaFrance
-
Innodem NeurosciencesSyneos HealthRecruiting
-
Innodem NeurosciencesNovartis PharmaceuticalsRecruitingMultiple SclerosisCanada
-
McGill UniversityInnodem NeurosciencesRecruitingClinically Isolated Syndrome | Relapsing Remitting Multiple SclerosisCanada
-
Innodem NeurosciencesSuspendedNeurological DisordersCanada
-
Instituto Universitario de Oftalmobiología Aplicada...Hospital del Río Hortega; Hospital Clínico Universitario de ValladolidCompletedMultiple Sclerosis | Eye Abnormalities | Parkinson Disease | Ataxia, Cerebellar | Injury BrainSpain
-
Innodem NeurosciencesNot yet recruiting
-
Innodem NeurosciencesRecruitingMultiple SclerosisCanada
-
Innodem NeurosciencesRecruitingCancer-related Cognitive ImpairmentCanada
-
Innodem NeurosciencesRecruitingAlzheimer's DiseaseCanada